Editas Medicine (NASDAQ: EDIT) is a leading biotechnology company that specializes in genome editing. Founded with a vision to harness the power of CRISPR technology, Editas Medicine is at the forefront of developing innovative therapies to address genetic diseases. Their groundbreaking research and development efforts have the potential to revolutionize the field of medicine by offering targeted treatments for a wide range of genetic disorders. Editas Medicine is dedicated to advancing precision medicine and improving patient outcomes through cutting-edge genome editing technologies.

Senior Director, Process Development

Scientist II, Molecular Biology & Gene Editing

Associate Corporate Counsel

Scientist I, In Vivo Discovery

Gene Editing Expert

Associate Corporate

Legal Counsel in Gene Editing

Research Associate, Molecular Bioanalytics

Senior Formulation Scientist

editas-medicine

Refer new talent to Editas Medicine